CEL-SCI Corp.
(NYSE Amex Equities : CVM)

( )
CVM After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen, Inc.
0.30%294.141.4%$886.90m
AMGNAmgen, Inc.
-0.19%220.701.3%$490.85m
CELGCelgene Corp.
0.03%109.571.3%$444.88m
GILDGilead Sciences, Inc.
-1.13%64.641.0%$396.62m
ILMNIllumina, Inc.
0.55%295.003.5%$302.62m
VRTXVertex Pharmaceuticals, Inc.
0.29%201.901.9%$286.11m
REGNRegeneron Pharmaceuticals, Inc.
0.73%344.282.6%$267.21m
EXASEXACT Sciences Corp.
-3.74%80.5324.0%$194.90m
ALXNAlexion Pharmaceuticals, Inc.
-1.61%109.012.0%$188.88m
SGENSeattle Genetics, Inc.
-0.04%108.306.1%$124.42m
BMRNBioMarin Pharmaceutical, Inc.
-0.75%75.334.3%$106.48m
AAgilent Technologies, Inc.
0.27%76.851.6%$101.75m
SRPTSarepta Therapeutics, Inc.
-1.56%94.7814.6%$90.92m
MRTXMirati Therapeutics, Inc.
-1.53%103.182.3%$88.52m
NBIXNeurocrine Biosciences, Inc.
0.07%110.855.0%$79.43m

Company Profile

CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients; and CEL-2000 and CEL-4000 which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.